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MURIA Group Introductory meeting ± Port Elizabeth, South Africa 27 ± 28 January 2015 
 
Abstract 
 
This two day meeting brought together drug utilisation researchers from across Africa. The purpose 
was to share current drug utilisation (DU) research findings to further DU research across Africa 
including the development of a medicines utilisation research group. This led to the formation of the 
MURIA (Medicine Utilisation Research in Africa) Group, with a tentative vision and mission as well as 
the first planned research methodology training course and a symposium in Botswana later in the 
year. Future research projects were also planned including studies on drug utilisation of ARVs in 
Botswana and across Africa as well as ways to enhance the appropriate use of antibiotics and 
increase generic utilisation.  
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Main body 
 
Pharmaceutical policy typically varies by income level and traditions; however, the goal in all 
countries is to enhance the rational use of medicines. In low income countries, households incur 
potentially catastrophic expenses when family members become ill. The principal policy goal therefore 
is to improve access to essential medicines in these countries to reduce maternal and child mortality 
as well as mortality from other highly prevalent diseases including AIDS, malaria, and tuberculosis. In 
higher income countries, the goal is to develop and maintain comprehensive and equitable healthcare 
in the face of growing pressures. This has resulted in multiple policies to improve the managed entry 
of new high-priced medicines as well as increase the prescribing of low cost generics to release 
valuable resources for re-direction including funding increased use of medicines with a growing 
elderly population (1, 2).  
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Countries need to learn from each other to achieve their goals since the unnecessary use of 
medicines has considerable resource implications. These include increasing the number of adverse 
events with the possibility of hospitalisation and death, increasing antibiotic resistance as well as 
potentially depriving patients of the benefits of medicines (3). This necessarily includes analysing 
treatment patterns alongside health policies in their own and surrounding countries, and using the 
findings to shape future policies. In Africa, this can also include researching complementary and 
alternative medicines (4). These issues and challenges resulted in an identified need to bring together 
researchers from across Africa to discuss their ongoing and future research to enhance the rational 
use of medicines. This was the principal driver behind the recent meeting in Port Elizabeth, the 
subsequent formation of the MURIA group and the progression of the first workshop in Botswana later 
in 2015.  
 
Main highlights of the meeting in Port Elizabeth (http://muria.nmmu.ac.za/Muria-Meeting-in-
Port-Elizabeth) 
 
Ilse Truter welcomed everyone to Port Elizabeth. Proceedings started with a brief history of activities 
to develop a Medicines Utilisation group in Africa building on other initiatives, notably the International 
Society for Pharmacoepidemiology (ISPE), EuroDURG and the recent World Congress for Basic and 
Clinical Pharmacology in South Africa (2014). This built on her considerable expertise, starting with 
the formation of the Drug Utilisation Research Group (DURU) in 1994. This has resulted in a constant 
stream of postgraduate students and publications, including central system medicines (5-9). 
 
Johanita Burger and her colleagues from the research entity Medicine Usage in Africa (MUSA) of the 
North West University (NWU) in South Africa subsequently discussed their extensive drug utilisation 
programme, which consists of four key research objectives:  
x To determine and compare medicine utilisation patterns and costs in Southern Africa 
x To evaluate the impact of policy decisions on the equity, affordability and availability of medicine 
x To investigate factors that may influence the appropriate use of medicine 
x To develop pharmaceutical care models to improve appropriate medicine usage 
 
Their research experience includes: (i) Pharmaceutical care / Clinical aspects to enhance appropriate 
use of medicine; (ii) Drug utilisation review and environmental influences on medicine usage; (iii) 
Pharmacoepidemiology / Pharmacoeconomics; (iv) Pharmacy practice with aspects including the 
standard, availability, access  and affordability of pharmaceutical services. This has resulted in 
multiple collaborations with other researchers across Africa (6, 7, 10, 11), which will continue. 
 
Jaran Eriksen presented a number of drug utilisation studies he has been involved with including 
optimizing dosing regimens for ARVs in children and adults in Uganda 
(https://openarchive.ki.se/xmlui/handle/10616/41587); mHealth projects in pregnant women with HIV 
and their newborns (South Africa); algorithms for optimizing treatment in critical care (Tanzania) as 
well as studies assessing needs and attitudes to the implementation of information and 
communication technology (ICT) for rational use of medicines among healthcare staff in rural 
Tanzania (12).  
 
Matthias Adorka discussed ongoing research in Namibia, which includes antibiotic prescribing 
practices in outpatient departments of public hospitals and affiliate clinics (10, 11) as well as (i) 
assessment of current antibiotic prescribing in respiratory tract infections; (ii) the development of a 
computerized algorithm for the appropriate prescribing of antibiotics in the treatment of respiratory 
tract infections in primary healthcare settings and (iii) Therapeutic Drug Monitoring of anti-TB drugs in 
drug resistant patients. Other projects included assessing gentamicin therapy in the elderly and 
whether there is a need to carry out renal function tests before commencing therapy using a 
pharmacokinetic approach. The methodology involves cross sectional and prospective studies 
including taking blood samples and serum creatinine measurements. The intention being to assess 
the association between development of gentamicin toxicity and gentamicin blood levels and 
population clearance in the target patient group to provide future guidance. 
 
Ongoing drug utilisation research in Nigeria includes potential ways to reduce drug: drug interactions 
(DDIs) in patients with HIV through physicians consulting more than one DDI database, studies 
demonstrating frequent medication errors among paediatric nurses and the use of complementary 
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and alternative medicines (4, 13-15). Other studies have shown that adherence to medicines to 
control hypertension has been poor with BP control remaining unsatisfactory, although other studies 
have shown that medication adherence and treatment satisfaction among psychiatric outpatients is 
generally good (16, 17). Studies have also shown high rates of polypharmacy and inappropriate 
prescribing among the elderly as well as low rates of generic prescribing and over use of antibiotics 
(18, 19). All these studies are aimed at identifying specific problems to address to enhance the 
rational use of medicines. 
  
Finally, Brian Godman discussed cross national studies undertaken with health authority personnel 
from across Europe to compare the impact of different demand-side measures to enhance the 
preferential prescribing of high quality low cost generics versus originators and patented products in a 
class where all products are seen as therapeutically equivalent at appropriate doses (2). Recent 
research has shown that countries are learning from each other with measures to enhance the 
utilisation of generics and this will continue (2). This research was facilitated by the development of 
the Piperska group (http://www.piperska.org/), whose early mission was "to ensure robust systems 
are in place in Europe to enhance the rational use of drugs, including new expensive drugs, to 
improve health".  
 
It was subsequently agreed there should be a pro-active group in Africa stimulating cross national 
research to enhance the rational use of medicines. This resulted in an agreed name ± the MURIA 
(Medicines Utilisation Research in Africa) group - with a draft vision and mission, which is currently 
being refined (http://muria.nmmu.ac.za/). The MURIA Group should be a multidisciplinary network of 
healthcare professionals striving to promote sustainable, rational medicine use in Africa. This can be 
achieved through collaborative research and capacity building, with the objective of improving the 
quality of life of patients, as well as the quality of medicine utilisation in Africa. It is intended that the 
vision of MURIA will be achieved through training, collaborative research, information sharing and 
facilitation of access to data across Africa. As a result, aiming to address current challenges regarding 
DU research in Africa (http://muria.nmmu.ac.za/). The first step is a 2.5 day workshop and symposium 
around drug utilisation in Gaborone, Botswana at the end of July 2015 
(http://muria.nmmu.ac.za/Botswana-Workshop-and-Symposium-27-29-July-2015), which will cater for 
all personnel including those just starting research in this area to those actively undertaking medicine 
utilisation research. This will be achieved through two workshop streams (parallel sessions) ± one 
Introductory and one advanced - including all aspects of drug utilisation research. Subjects include 
basic and advanced methodologies including challenges, ways to influence prescribing behaviour, 
basic and advanced statistics as well as discussions on ethics, databases and communication 
programmes. The speakers are principally those who took part in the inaugural MURIA meeting in 
Port Elizabeth. 
 
The workshop will be followed by a symposium for researchers to present their projects and findings, 
with drug utilisation of ARVs a principal theme. This will allow workshop attendees to see some of the 
theory put into practice. The registration fees have been kept deliberately low to attract researchers 
from right across Africa, made possible by a grant from the Swedish Research Council to develop 
drug utilisation research around ARVs in Botswana.  
 
A number of research projects are also ongoing. These included projects summarising key health 
care characteristics among African countries including Botswana, South Africa, Namibia, Swaziland, 
Lesotho, Nigeria, Zimbabwe, Ghana, Tanzania, Uganda, Kenya, Rwanda and Ethiopia, incorporating 
total health and pharmaceutical expenditure, key characteristics around health care provision and its 
financing. In addition, data base characteristics in each country as well as current DU capabilities. 
Initial disease areas for comparing utilisation and policies across countries include antibiotics and 
ARVs. This will start with southern Africa countries, building on previous research surrounding 
antibiotics (6, 10, 11, 18, 20). Other research topics include policies surrounding generics as well as 
complementary and alternative medicines. 
 
Overall, it was a highly fruitful meeting in Port Elizabeth laying the foundation for an interactive and 
productive MURIA group. 
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